News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 


LCT Parkinson’s trial resumes patient recruitment

LCT Parkinson’s trial resumes patient recruitment

23 June 2014 – Sydney, Australia & Auckland, New Zealand – Living Cell Technologies Limited today announced that it has received the necessary regulatory approval to resume recruitment of the remaining three patients in the Phase I/IIa clinical trial of NTCELL® in Parkinson’s disease. The trial was paused in December last year while the company completed internal and external audit and regulatory processes.

Dr Ken Taylor, NTCELL Program Director and Acting Chief Executive, is pleased that patient recruitment in the clinical trial of NTCELL for Parkinson’s can resume.

“The completion of the clinical trial is an initial step in progressing NTCELL to commercialisation as the first disease modifying treatment for Parkinson’s disease.”

Existing treatments for Parkinson’s treat the symptoms rather than attempting to regenerate the affected brain cells. Many people with Parkinson’s no longer respond to these treatments.

“LCT is committed to developing and marketing NTCELL for Parkinson’s patients not responding to current therapies. We also intend to further investigate the potential of our patented cell therapy as a treatment for other neurodegenerative disorders,” said Dr Taylor.

Preclinical studies which confirmed NTCELL initiated nerve growth support the development of NTCELL as a potential treatment for other neurological diseases such as Huntington’s, Motor Neuron and Alzheimer’s.

For further information: www.lctglobal.com

About Living Cell Technologies
Living Cell Technologies (LCT) is an Australasian biotechnology company researching and developing cell therapies to treat diseases with high unmet clinical need. LCT’s lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration.

NTCELL is in Phase I/IIa clinical trial in New Zealand for the treatment of Parkinson’s disease. It has the potential to be used in a number of indications.

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development, operations and manufacturing facilities based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

ENDS

© Scoop Media

 
 
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 

Werewolf: Music Criticism As A Dating Metaphor

Music criticism can be just another form of consumer advic... Yet ever since pop music criticism first entered the media mainstream it has played a wider role, too. Rather than a decree with a numerical score attached, this kind of criticism functions more like travel notes. A conversation, even a form of seduction. More>>

ALSO:

Scoop Review Of Books: Rushing For Gold

The first section focuses particularly on the Victorian connections – commercial, legal, mining and personal, including migration statistics. But for me the most interesting chapters were in the middle sections about the people of the goldfields. More>>

Comedy Festival Review: VOTE BATT

The political campaigning in the US over the last eight months or so has provided a stark insight into how far political candidates are willing to go. This background came into focus as “former comedian” – now politician – Tim Batt ushered people up into the front seats, passing out badges and taking photographs with his not entirely adoring public... More>>

HRH QEII's 90th: New Zealand Post Birthday Stamps Fit For A Queen

New Zealand Post is celebrating the Queen’s 90th birthday with a special series of stamps and a limited edition silver coin. The Queen was born on 21 April 1926. To mark her birthday, New Zealand Post has produced ‘lenticular’ or moving stamps that feature nine different images of the Queen on just three stamps. More>>

ALSO:

Anzac Day: A Time To Stand Against Hatred

The Human Rights Commission says ANZAC Day is a time for New Zealanders to remember those things our grandparents stood for and stand up against intolerance and prejudice. More>>

ALSO:

Get More From Scoop

 
 

LATEST HEADLINES

 
 
 
 
Health
Search Scoop  
 
 
Powered by Vodafone
NZ independent news